Getting Rid of Weakness in the ICU: An Updated Approach to the Acute Management of Myasthenia Gravis and Guillain-Barré Syndrome

Abstract

After prompt diagnosis, severe myasthenia gravis and Guillain-Barré syndrome (GBS) usually require management in the intensive care unit. In the myasthenic patient, recognition of precipitating factors is paramount, and frequent monitoring of bulbar, upper airway, and/or respiratory muscle strength is needed to identify impending myasthenic crisis. Noninvasive ventilation can be attempted prior to intubation and mechanical ventilation in the setting of respiratory failure. Cholinesterase inhibitors should be discontinued, but resumed prior to extubation, and steroid dosage could be increased once the airway is secured. In GBS, hemodynamic and respiratory monitoring are essential; however, respiratory failure can develop rapidly and intubation with mechanical ventilation is often required and can be prolonged. Guillain-Barré syndrome can also be complicated by dysautonomia necessitating specific therapies. Prompt recognition and initiation of immunotherapy including intravenous immunoglobulin or plasmapheresis, together with supportive care including treatment of underlying infections and physical therapy, can improve outcomes in both myasthenic crisis and GBS.

Thymectomy immediately after myasthenic crisis

“…The authors did not agree about cholinesterase inhibitors and MC; according to some, it is recommended in the crisis (5) while most agree that it should be discontinued (6,7).…”

ICU related neuromuscular complications

“…26 Autonomic involvement is also commonly seen, presenting as postural hypotension, fluctuation in blood pressure, and cardiac dysrhythmias. 20,[26][27][28] Respiratory paralysis is the most common indication for ICU admission. 20 About 30% of patients require ventilator support at some time during the illness.…”

Advanced Comprehensive Rehabilitation Approach for Post-operative patient with Anterior Mediastinal Tumor: Atypical Case Report

“…Myasthenia gravis (MG) is an chronic autoimmune disease (Calik-Kutukcu et al, 2019) in which muscle weakness (Lizarraga et al, 2016) and fatigability of the voluntary skeletal muscular muscles are due to an antibody at the neuromuscular junction against the acetylcholine receptor (AChR) (Kang et al, 2007). The important cardinal symptoms of MG is muscle fatigue followed by Ptosis, Ocular myasthenia, diplopia, changes in facial expression, problem in swallowing, shortness of breath, and defect of speech .…”